Handok, the total healthcare company.
Handok improves the health of human and the quality of life with the good quality of products and services
Pipelines
Look into the wide range of our products.
-
PRRezolute, Largely Owned by Handok and Genexine, Announces Major Result of U.S. Clinical Trial Phase Ib for Oral Diabetic Macular Edema Treatment RZ402
On February 22, 2022 (local time), Rezolute, Inc., a U.S. bio-venture in which Handok and Genexine are the largest shareholders, announced a major positive outcome during the U.S. Phase Ib mul..
2022.02.23 -
PRHandok Signs Domestic Joint Promotion and Sales Agreement with Sanofi-Aventis Korea for Treatment of Hyperphosphatemia Using Renvela
On February 10, 2022, Handok signed a domestic joint promotion and sales agreement with Sanofi-Aventis Korea (Bae Kyung-eun, CEO) for Renvela, a treatment for hyperphosphatemia, at Handok h..
2022.02.11 -
PR
Handok wins U.S. FDA Approval for Phase II Clinal Trial for Next-Generation Anticancer Treatment ABL001 (CTX-009)
Compass Therapeutics, a U.S. company in collaboration with Handok, received approval on January 18, 2022 (local time) for its Phase II clinical trial plans (Investigational New Drug Application..
2022.01.21
-
PR
Rezolute, Largely Owned by Handok and Genexine, Announces Major Result of U.S. Clinical Trial Phase Ib for Oral Diabetic Macular Edema Treatment RZ402
On February 22, 2022 (local time), Rezolute, Inc., a U.S. bio-venture in which Handok and Genexine are the largest shareholders, announced a major positive outcome during the U.S. Phase Ib mul..
2022.02.23 -
PR
Handok Signs Domestic Joint Promotion and Sales Agreement with Sanofi-Aventis Korea for Treatment of Hyperphosphatemia Using Renvela
On February 10, 2022, Handok signed a domestic joint promotion and sales agreement with Sanofi-Aventis Korea (Bae Kyung-eun, CEO) for Renvela, a treatment for hyperphosphatemia, at Handok h..
2022.02.11
Website
You can see the various brands of Handok.
